1699 results about "Inactivated vaccine" patented technology

The invention discloses a porcine pseudorabies virus virulent strain, and a gene deletion vaccine strain thereof and applications thereof. The porcine pseudorabies virus virulent strain is named as HeN1, the microbial preservation number of the porcine pseudorabies virus virulent strain is CGMCC NO.6656, the deleted gE gene obtaines the gene deletion vaccine strain rPRV-gE-EGFP+ on the basis of the virulent strain HeN1, and the microbial preservation number is CGMCC NO.6657. The virulent strain can be prepared into inactivated vaccine (single vaccine or combined vaccine), the gene deletion vaccine strain rPRV-gE-EGFP+ can be prepared into activated vaccine or inactivated vaccine (single vaccine or combined vaccine) and the like, so that porcine pseudorabies can be effectively prevented or cured, or the gene deletion vaccine strain rPRV-gE-EGFP+ can be prepared into a diagnosis reagent for diagnosing the porcine pseudorabies. The gene deletion vaccine strain rPRV-gE-EGFP+ has the advantages of being good in safety, high in protection efficiency, beneficial to differential diagnosis.

The present invention encompasses influenza vaccines, in particular avian influenza vaccines. The vaccine may be a recombinant poxvirus vaccine or an inactivated vaccine. The invention also encompasses recombinant poxvirus vectors encoding and expressing avian influenza antigens, epitopes or immunogens which can be used to protect animals, in particular felids, against avian influenza.

The present invention relates to providing new vaccines and treatments for the diseases related to canine influenza virus. It discloses influenza viral antigens, and methods of presenting these antigens to canines, especially dogs. It relates to attenuated and killed vaccines. The present invention relates to experimentally generated canine and equine influenza viruses. The invention also includes influenza A, including H3, N8, H3N8, H7N7 and viruses which contain at least one genome segment from an canine or equine influenza virus. The present invention also relates to the use of these viruses in therapeutic compositions to protect canines, dogs in particular, from diseases caused by influenza viruses.

The present invention belong to veterinary new biological medicine technology field, relates to porcine circovirus type II (PCV2) inactivated vaccine of and method for preparing same. The vaccine used seed virus is porcine circovirus type II DBN-SX07 strain, the preservation number is CGMCC No 3064, the virus strain is used as antigen preparation of inactivation by alkyl agents and emulsification by adding oil adjuvant. Using the invention provided PCV2 inactivated vaccine to immune pig can generate an uniform and effective protection force-shorting PCV2 infection windows period obviously, and prolong immune duration-reducing times of booster immunization.

The invention provides a novel haemophilus parasuis disease trivalent inactivated vaccine and a preparation method thereof. The vaccine comprises equal proportions of antigens of: inactivated haemophilus parasuis serotype 4 JS strain, inactivated haemophilus parasuis serotype 5 ZJ strain, and inactivated haemophilus parasuis serotype 12 HeB strain. According to the invention, the haemophilus parasuis serotype 4, serotype 5, and serotype 12 strains are obtained by separation. Concentration contents and relative proportions of the antigens prepared from the three strains are subjected to large amounts of woks and practices, such that the trivalent vaccine with an appropriate antigen ratio and an appropriate concentration is obtained. The trivalent vaccine has good preventing and treating effects against haemophilus parasuis diseases caused by various epidemic haemophilus parasuis serotypes in our nation. Especially, the trivalent vaccine can solve a problem of poor treatment effect of existing vaccines caused by novel haemophilus parasuis pathogens.

The invention discloses a virulent strain HuN4 for porcine reproductive and respiratory syndrome, and an attenuated vaccine strain HuN4-F112 (the collection number of microorganism: CGMCC No.2484) attenuated because of virulent strain HuN4 passage, and also discloses the application of the attenuated vaccine strain in preventing or curing the highly pathogenic blue-ear disease, which belongs to the biomedical field. The attenuated vaccine strain HuN4-F112 can be prepared into single-vaccine or combined strain (live vaccine or inactivated vaccine), can effectively prevent or cure the highly pathogenic blue-ear disease, and also can be prepared into diagnostic reagent for the highly pathogenic blue-ear disease diagnosis. The attenuated vaccine strain HuN4-F112 of the invention has the advantages of good security and high protection efficiency.

We have generated novel molecularly marked FMDV A₂₄LL3D_YR and A₂₄LL3B_PVKV3D_YR vaccine candidates. The mutant viruses contain a deletion of the leader coding region (LL) rendering the virus attenuated in vivo and negative antigenic markers introduced in one or both of the viral non-structural 3D^pol and 3B proteins. The vaccine platform includes unique restriction endonuclease sites for easy swapping of capsid proteins for different FMDV subtypes and serotypes. The mutant viruses produced no signs of FMD and no shedding of virulent virus in cattle. No clinical signs of disease or fever were observed and no transmission to in-contact animals was detected in pigs inoculated with live A₂₄LL3D_YR. Cattle immunized with chemically inactivated vaccine candidates showed an efficacy comparable to a polyvalent commercial FMDV vaccine. These vaccine candidates used in conjunction with a cELISA provide a suitable target for DIVA companion tests.

A recombinant Pseudorabies virus PrV gene engineering strain WKQ-001, inactivated vaccine containing the poisonous strain and its use are disclosed. It can be used to discriminate and diagnose artificial immunity pig or natural infectious pig. It's safe and doesn't contain exogenous gene.

The invention discloses a univalent and bivalent inactivated vaccine for preventing Enterovirus 71 (EV71) and Coxsackie virus A16 (Cox.A16) of hand-foot-and-mouth disease, and a preparation method thereof. The preparation method comprises the following steps: screening vaccine strains for the hand-foot-and-mouth disease; establishing and verifying a vaccine strain third-stage seed lot library; culturing cells; inoculating and propagating virus; collecting virus suspension; inactivating the virus; ultra-filtering, concentrating and purifying the virus suspension to obtain vaccine stock solution; and finally preparing the univalent and bivalent inactivated vaccine. The univalent and bivalent inactivated vaccine has good application prospect for preventing the hand-foot-and-mouth disease.

The invention provides a fusion protein, a porcine epidemic diarrhea vaccine composition containing the fusion protein and application thereof. The fusion protein contains porcine epidemic diarrhea virus antigenic protein and immunoglobulin Fc segment, wherein the porcine epidemic diarrhea virus antigenic protein contains a protein formed by series combination of porcine epidemic diarrhea virus S protein segments. The invention also provides a porcine epidemic virus vaccine composition which contains the fusion protein and a carrier. The invention also provides a preparation method of the vaccine composition and application of the vaccine composition in preparing drugs for preventing and/or treating diseases initiated by porcine epidemic diarrhea virus. The vaccine composition prepared from the fusion protein avoids the technical problem that the porcine epidemic diarrhea virus totivirus can not be easily separated and cultured in the traditional vaccine inactivation process. The fusion protein can utilize the gene engineering technique to perform abundant recombinant expressions, has the advantage of short time consumption, and is convenient for large-scale production.

The invention discloses a porcine streptococcus disease and haemophilus parasuis disease combined inactivate vaccine and a preparation method thereof. The preparation method comprises the following steps of: a, respectively carrying out enrichment culture on a porcine streptococcus strain, a haemophilus parasuis strain and a haemophilus parasuis strain to obtain a porcine streptococcus strain bacterial solution, a haemophilus parasuis strain bacterial solution and a haemophilus parasuis strain bacterial solution; b, respectively adding a formaldehyde solution into the porcine streptococcus strain bacterial solution, the haemophilus parasuis strain bacterial solution and the haemophilus parasuis strain bacterial solution, and inactivating; c, mixing the collected porcine streptococcus strain bacterial solution, the haemophilus parasuis strain bacterial solution and the haemophilus parasuis strain bacterial solution, adding Tween-80 for preparing a water phase, preparing white oil, Span-80 and aluminium stearate into an oil phase, mixing the water phase with the oil phase to prepare a uniform emulsion, i.e. an oil emulsion inactivating vaccine; and 4, sub-packaging the oil emulsion inactivating vaccine. The porcine streptococcus disease and haemophilus parasuis disease combined inactivate vaccine can effectively prevent the porcine streptococcus disease and haemophilus parasuis disease, does not have hidden danger of scattering viruses and is safe and reliable; and the immunization is realized by one vaccine, thus the cost is reduced.

The invention relates to an emulsion breaking method for an aftosa oil emulsion inactivated vaccine used in an aftosa vaccine quality detection technology. The method comprises the following steps of: fully and uniformly mixing an emulsion breaking agent with an aftosa oil emulsion inactivated vaccine; standing; separating oil from water; and distributing aftosa virus particles into a water phase, wherein the emulsion breaking agent is selected from any of benzyl alcohol, n-amyl alcohol, chloroform and hexyl alcohol serving as organic solvents. Due to the adoption of the method, the completeness of aftosa virus particles 146S is not broken basically, emulsion is broken rapidly and simply, the antigen 146S recovery rate is high, and the stability is high; and the method is particularly suitable to be taken as a method for monitoring the quality of commercial aftosa vaccines for aftosa vaccine producing enterprises and the national quality test departments.

The invention provides a combined inactivated vaccine against mycoplasma hyopneumoniae (MHP) and mycoplasma hyorhinis. The combined inactivated vaccine contains the MHP and the mycoplasma hyorhinis with preferred content as well as a Carbomer adjuvant with concentration of 10% (V/V). The invention further provides a preparation method of the combined inactivated vaccine against the MHP and the mycoplasma hyorhinis. The preparation method comprises the following steps: preparing production strains; preparing bacterium solution for producing seedlings; and inactivating, concentrating and blending to obtain the vaccine. The combined inactivated vaccine has the advantages of strong specificity and good immunity, thus solving the problem of specific infection caused by the MHP in the current domestic breeding farm and obtaining the mycoplasma hyorhinis vaccine under a blank state at home and abroad at present. The combined inactivated vaccine has the beneficial effects that the step of vaccine inoculation is simplified, trouble caused by a plurality of inoculation and easily produced side effects are avoided, and vaccine cost is saved, thus being especially applicable to preventing andtreating mixed infection diseases in the breeding farms at home and abroad and the like; and compared with the existing single vaccine, application range is widened and immune effect is enhanced.

The invention discloses rhodococcus ruber and application of same as an immunologic adjuvant in preparing vaccine. The rhodococcus ruber is also called rhodococcus ruber RDC-01, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) NO. 16640. The rhodococcus ruber disclosed by the invention has the function of increasing and regulating the body immunity andis capable of nonspecifically enhancing the activity of TB (Tuberculosis) lymphocyte, macrophagocyte and NK cells and inducing multiple cell factors such as interferon, and the rhodococcus ruber canbe used as the immunologic adjuvant after being inactivated so as to be added in an oil-adjuvant inactive vaccine, so that generation of an animal antibody induced by the vaccine can be obviously promoted; compared with single use of the oil-adjuvant inactive vaccine, a high-titre antibody can be generated, the use is safe, long-term and short-term toxic and side effects are not generated, and anapplication prospect in the field of preparation of vaccines for animals is good.

The invention discloses a porcine epizootic diarrhea virus strain with good immunogenicity and an inactivated vaccine prepared through the porcine epizootic diarrhea virus strain. The porcine epizootic diarrhea virus strain is a current epidemic strain, and good immunogenicity and stability are achieved; compared with a commercially available vaccine strain, the vaccine prepared through the strain has the advantages of being good in safety, high in immune protective capability, high in immune efficacy and the like, and porcine epizootic diarrhea can be comprehensively and effectively prevented and treated.

The invention discloses a bactrian camel heavy-chain (HC) variable-domain antibody resisting a porcine circovirus 2 as well as a preparation method and an application thereof, and belongs to the field of a biotechnology. A PCV2 (Porcine Circovirus Virus) inactivated vaccine immunized bactrian camel is firstly utilized and a phage display technology is utilized to establish a PCV2 immune VHH antibody base; and a high-specificity variable domain antibody of heavy chains of HCAbs (VHH) which has a good affinity with the PCV, particularly a PCV2 virus antigen; and the antibody disclosed by the invention has an amino acid sequence shown as SEQ (sequence) ID NO.1 or an amino acid sequence which is shown as SEQ ID NO.2 and has the sequence isogeny being more than 95%. The PCV2 heavy-chain variable-domain antibody disclosed by the invention has the very important meanings on researching porcine circovirus, particularly researching a porcine circovirus 2-type infection mechanism and establishing rapid antigen detection with high sensitivity and specificity or diagnosing a reagent.

The invention discloses a nose-spraying flu immunization pentavalent or multivalent inactivated vaccine and preparation method thereof. The vaccine is inactivated vaccine antigen of totivirus, lytic virus, viron or virus-like particles, flue multivalent vaccine antigen is flue pentavalent, namely H1N1, H3N2, B, H5N1 and A (H1N1) or multivalent vaccine antigen combined on the basis at will, or flue multivalent vaccine antigen obtained by containing all the combination of the HA selecting from H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15 and H16 and the NA selecting from N1, N2, N3, N4, N5, N6, N7, N8 and N9 subtypes on the basis. The content of flu multivalent inactivated vaccine antigen HA in the vaccine of the invention is 1.0-15.0 Mug/0.2ml/per person, and the vaccine of the invention can effectively prevent routine human flue, high pathogenicity H5N1 avian-human flu, influenza A (H1N1) and infection of other subtype influenza viruses.

The invention discloses a porcine reproductive and respiratory syndrome divalent recombination adenovirus vaccine and the preparation method thereof. The invention belongs to the technical field of biological vaccine preparation. The vaccine can be prepared by the following steps: a GP5-2A-M fusion protein gene can be constructed by inserting an FMDV2A gene with self craking between PRRSV GP5 and M protein; homologous recombination is carried out on the GP5-2A-M fusion protein gene and adenovirus backbone plasmid pAdEasy-1; recombination adenovirus rAd-GP5-2A-M is prepared by restriction enzyme and HEK-293A cells transfection, and the divalent recombination adenovirus vaccine is prepared by the technology and the steps such as purification, amplification, and the like. After expression, the aggregate protein GP5-2A-M constructed by the invention is self cracked into GP5 and M protein, as well as exerts the viral neutralization of GP5 and the immune function of the M protein; the vaccine has stable titer with the virulent valence being 10<10.43>TCID<50>/1.0ml, as well as has both the duplication characteristic of a routine attenuated vaccine and the safety of an inactivated vaccine; the divalent recombination adenovirus vaccine can be popularized in and applied to the control work of porcine reproductive and respiratory syndrome.

The invention discloses a special diluent for swine mycoplasmal pneumonia vaccines. The special diluent mainly contains a recombinant P97R1 protein immunostimulating complex (ISCOM-P97R1); and in addition, the special diluent also possibly contains other water-based adjuvants comprising levomisole, astragalus polysaccharide or/and carbomer. 1 ml of diluent solution contains 0.1-1 mg of QuilA, 0.02-0.2 mg of cholesterol, 0.02-0.2 mg of phosphatidylcholine and 0.4-4 mg of P97R1 antigen; and in addition, 1 ml of diluent solution also possibly contains 2-20 mg of levomisole, 20-100 mg of astragalus polysaccharide or/and 3-10 mg of carbomer and a phosphate buffer solution for the rest. The diluent is specially used for dissolving or diluting the swine mycoplasmal pneumonia vaccines comprising a live vaccine and an inactivated vaccine, has the double effects of complementing vaccine antigen protection spectrums and improving the vaccine cell and humoral immunostimulation capability, can remarkably improve the toxic attack protection efficacy of the vaccines, and also has the advantages of being simple and convenient to operate, good in syringeability and free from remarkable toxic side reaction due to the adoption of a hydrosolvent system at the same time.